An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.

Adjuvant therapy with nivolumab (Opdivo, “nivo”) continues to show disease-free survival (DFS) and overall survival (OS) benefits compared with placebo among patients with muscle-invasive ...

In a study of patients with advanced melanoma, the prevalence of cutaneous immune–related adverse events (cirAEs) associated with nivolumab/relatlimab combination therapy was 21.5%, with rash ...

This trial is looking at adding SCIB1 or iSCIB1+ to nivolumab and ipilimumab for melanoma. It is also looking at adding SCIB1 to pembrolizumab for melanoma. It is for people whose melanoma has grown ...

Adjuvant nivolumab improves DFS in MIBC patients, regardless of prior neoadjuvant chemotherapy, with a median DFS of 25.6 months versus 8.5 months with placebo. Overall survival rates at 24 and 36 ...

Bristol Myers BMY announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo ...